多发性骨髓瘤治疗药物:到2018年为止的开发平台评估与市场预测 是由出版商GlobalData在2011年10月所出版的。
这份英文市场调查报告书包含Pages: 111 价格从美金3500起跳。
多发性骨髓瘤市场在2010年达到34亿美金的规模。预测今后也将以年复合成长率7.1%扩大，到2018年将达到60亿美金的规模。Velcade及Revlimid的摄取量增加是该市场成长的主因。虽然新开发的分子也将上市，但这些分子只限于使用在再发作及难根治的多发性骨髓瘤患者身上，因此一般认为对市场的影响应该仅止于最小。
本报告提供多发性骨髓瘤的概要与诊断，概论治疗方法，治疗药物市场的规模与2018年为止的预测，汇整主要各市场趋势，开发平台，参与企业简介等数据，为您概述为以下内容。
第1章 目录
第2章 多发性骨髓瘤治疗药物:简介
- 疾病概要
- 免疫学
- 病因及危险因素
- 症状
- 诊断
- 多发性骨髓瘤的分期设定
- 多发性骨髓瘤的治疗方法
- 报告指南
第3章 市场特徵
- 全球市场规模(2005～2010年)
- 全球市场预测(2010～2018年)
- 美国市场规模
- 美国市场预测
- 法国市场规模
- 法国市场预测
- 德国市场规模
- 德国市场预测
- 义大利市场规模
- 义大利市场预测
- 西班牙市场规模
- 西班牙市场预测
- 英国国市场规模
- 英国市场预测
- 日本市场规模
- 日本市场预测
- 推动市场的要素与阻碍要素
- 机会与未满足需求分析
- 要点
第4章 竞争评估
- 概要
- 策略性竞争企业评估
- 已上市的主要产品简介
- Velcade
- Thalomid
- Revlimid
- 要点
第5章 开发平台评估
- 概要
- 策略性开发平台评估
- 各开发阶段开发平台
- 各作用机制开发平台
- 临床开发中的潜力治疗药物简介
- 要点
第6章 临床实验蓝图
- 各国
- 各阶段
- 各治疗状况
- 整体临床实验委托者
- 主要临床实验委托者
- 参与计划的主要企业
第7章 策略性评估
第8章 未来的企业
- 简介
- 企业简介
- Bristol-Myers Squibb Company
- AEterna Zentaris Inc
- Celgene Corporation
- Merck & Co., Inc
- Novartis AG
- Onyx Pharmaceuticals, Inc
- Johnson & Johnson
- PharmaMar, S.A.
第9章 专利与合作交易
第10章 附录
图表
Abstract
Summary
GlobalData, the industry analysis specialist, has released its new report, "Multiple Myeloma Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Multiple Myeloma Therapeutics market. The report identifies the key trends shaping and driving the global Multiple Myeloma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Multiple Myeloma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Multiple Myeloma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Multiple Myeloma Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Multiple Myeloma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Multiple Myeloma Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Multiple Myeloma Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Multiple Myeloma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Multiple Myeloma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Multiple Myeloma Therapeutics market landscape? - Identify, understand and capitalize.
Table of contents
1. Table of contents
- 1.1 List of Tables
- 1.2 List of Figures
2. Multiple Myeloma Therapeutics - Introduction
- 2.1 Disease Overview
- 2.2 Epidemiology
- 2.3 Etiology and Risk Factors
- 2.4 Symptoms
- 2.5 Diagnosis
- 2.5.1 M Band Electrophoresis
- 2.5.2 Complete Blood Count (CBC)
- 2.5.3 Quantitative Immunoglobulins
- 2.5.4 Blood Chemistry Test
- 2.5.5 Bone X-Rays
- 2.5.6 Computerized Tomography (CT)
- 2.5.7 Magnetic Resonance Imaging (MRI
- 2.5.8 Positron Emission Tomography (PET)
- 2.5.9 Bone Marrow Biopsy
- 2.6 Staging for Multiple Myeloma
- 2.6.1 Durie-Salmon System of Staging
- 2.6.2 International Staging System
- 2.6.3 Other Stages of Multiple Myeloma
- 2.7 Treatment for Multiple Myeloma
- 2.7.1 Chemotherapy
- 2.7.2 Immunotherapy
- 2.7.3 Radiation Therapy
- 2.7.4 Bone Marrow Transplants
- 2.7.5 Stem Cell Transplants
- 2.8 GlobalData Pipeline Report Guidance
3. Multiple Myeloma Therapeutics - Market Characterization
- 3.1 Multiple Myeloma Therapeutics Market Size (2005-2010) - Global
- 3.2 Multiple Myeloma Therapeutics Market Forecast (2010-2018) - Global
- 3.3 Multiple Myeloma Therapeutics Market Size (2005-2010) - The US
- 3.4 Multiple Myeloma Therapeutics Market Forecast (2010-2018) - The US
- 3.5 Multiple Myeloma Therapeutics Market Size (2005-2010) - The UK
- 3.6 Multiple Myeloma Therapeutics Market Forecast (2010-2018) - The UK
- 3.7 Multiple Myeloma Therapeutics Market Size (2005-2010) - France
- 3.8 Multiple Myeloma Therapeutics Market Forecast (2010-2018) - France
- 3.9 Multiple Myeloma Therapeutics Market Size (2005-2010) - Germany
- 3.10 Multiple Myeloma Therapeutics Market Forecast (2010-2018) - Germany
- 3.11 Multiple Myeloma Therapeutics Market Size (2005-2010) - Italy
- 3.12 Multiple Myeloma Therapeutics Market Forecast (2010-2018) - Italy
- 3.13 Multiple Myeloma Therapeutics Market Size (2005-2010) - Spain
- 3.14 Multiple Myeloma Therapeutics Market Forecast (2010-2018) - Spain
- 3.15 Multiple Myeloma Therapeutics Market Size (2005-2010) - Japan
- 3.16 Multiple Myeloma Therapeutics Market Forecast (2010-2018) - Japan
- 3.17 Drivers and Barriers for the Multiple Myeloma Therapeutics Market
- 3.17.1 Drivers for the Multiple Myeloma Therapeutics Market
- 3.17.2 Barrier for the Multiple Myeloma Therapeutics Market
- 3.18 Opportunity and Unmet Need Analysis
- 3.18.1 Opportunity and Unmet Need for First Line Treatment of Multiple Myeloma
- 3.18.2 Opportunity and Unmet Need for Treatment of Relapse/Refractory Multiple Myeloma
- 3.19 Key Takeaway
4. Multiple Myeloma Therapeutics - Competitive Assessment
- 4.1 Overview
- 4.2 Strategic Competitor Assessment
- 4.2.1 Strategic Competitor Assessment - First Line Therapy
- 4.2.2 Strategic Competitor Assessment - Relapse/ Refractory Multiple Myeloma Therapy
- 4.3 Product Profiles for the Major Marketed Products in the Multiple Myeloma Therapeutics Market
- 4.3.1 Velcade (bortezomib)
- 4.3.2 Thalomid / Thaled (thalidomide)
- 4.3.3 Revlimid (lenalidomide)
- 4.4 Key Takeaway
5. Multiple Myeloma Therapeutics - Pipeline Assessment
- 5.1 Overview
- 5.2 Strategic Pipeline Assessment
- 5.3 Multiple Myeloma Therapeutics - Pipeline by Phases of Development
- 5.3.1 Multiple Myeloma Therapeutics - Phase III Pipeline
- 5.3.2 Multiple Myeloma Therapeutics - Phase II/III Pipeline
- 5.3.3 Multiple Myeloma Therapeutics - Phase II Pipeline
- 5.3.4 Multiple Myeloma Therapeutics - Phase I/II Pipeline
- 5.3.5 Multiple Myeloma Therapeutics - Phase I Pipeline
- 5.3.6 Multiple Myeloma Therapeutics - Preclinical Pipeline
- 5.3.7 Multiple Myeloma Therapeutics - Discovery Pipeline
- 5.4 Multiple Myeloma Therapeutics - Clinical Pipeline by Mechanism of Action
- 5.4.1 Technology Trends Analytical Framework
- 5.4.2 Technology Trend Analytical Framework Description
- 5.5 Multiple Myeloma Therapeutics - Promising Drugs with Novel Mechanisms of Action under Clinical Development
- 5.6 Profiles of Promising Drugs under Clinical Development
- 5.6.1 Actimid (pomalidomide)
- 5.6.2 Carfilzomib
- 5.6.3 Elotuzumab (HuLuc63)
- 5.6.4 Panobinostat (LBH589)
- 5.6.5 Perifosine (KRX-0401)
- 5.6.6 Aplidin (plitidepsin)
- 5.6.7 Siltuximab
- 5.6.8 Zolinza (vorinostat)
- 5.7 Key Takeaway
6. Multiple Myeloma Therapeutics - Clinical Trials Mapping
- 6.1 Clinical Trials by Country
- 6.2 Clinical Trials by Phase
- 6.3 Clinical Trials by Trial Status
- 6.4 Overall Sponsors
- 6.5 Prominent Sponsors
- 6.6 Top Companies Participating in Therapeutics Clinical Trials
7. Multiple Myeloma Therapeutics - Strategic Assessment
- 7.1 Key Events Impacting the Future Market
- 7.2 Implications for Future Market Competition
8. Multiple Myeloma Therapeutics - Future Players
- 8.1 Introduction
- 8.2 Company Profiles
- 8.2.1 Bristol-Myers Squibb Company
- 8.2.2 AEterna Zentaris Inc
- 8.2.3 Celgene Corporation
- 8.2.4 Merck & Co., Inc.
- 8.2.5 Novartis AG
- 8.2.6 Onyx Pharmaceuticals, Inc.
- 8.2.7 Johnson & Johnson
- 8.2.8 PharmaMar, S. A.
9. Multiple Myeloma (MM) Therapeutics - Licensing and Partnership Deals
10. Multiple Myeloma Therapeutics - Appendix
- 10.1 Market Definitions
- 10.2 Abbreviations
- 10.3 Methodology
- 10.3.1 Coverage
- 10.3.2 Secondary Research
- 10.3.3 Forecasting
- 10.3.4 Primary Research
- 10.3.5 Expert Panel Validation
- 10.4 Contact Us
- 10.5 Disclaimer
- 10.6 Bibliography
List of Tables
- Table 1: Normal CBC Levels
- Table 2: Multiple Myeloma - Durie-Salmon System of Staging
- Table 3: Multiple Myeloma - International Staging System
- Table 4: Multiple Myeloma - Treatment Options by Stages
- Table 5: Multiple Myeloma Therapeutics Market, Global, Revenue ($bn), 2005-2010
- Table 6: Multiple Myeloma Therapeutics Market, Global, Forecast ($bn), 2010-2018
- Table 7: Multiple Myeloma Therapeutics Market, The US, Revenue ($bn), 2005-2010
- Table 8: Multiple Myeloma Therapeutics Market, The US, Revenue ($bn), 2010-2018
- Table 9: Multiple Myeloma Therapeutics Market, The UK, Revenue ($m), 2005-2010
- Table 10: Multiple Myeloma Therapeutics Market, The UK, Forecast ($m), 2010-2018
- Table 11: Multiple Myeloma Therapeutics Market, France, Revenue ($m), 2005-2010
- Table 12: Multiple Myeloma Therapeutics Market, France, Forecast ($m), 2010-2018
- Table 13: Multiple Myeloma Therapeutics Market, Germany, Revenue ($m), 2005-2010
- Table 14: Multiple Myeloma Therapeutics Market, Germany, Forecast ($m), 2010-2018
- Table 15: Multiple Myeloma Therapeutics Market, Italy, Revenue ($m), 2005-2010
- Table 16: Multiple Myeloma Therapeutics Market, Italy, Forecast ($m), 2010-2018
- Table 17: Multiple Myeloma Therapeutics Market, Spain, Revenue ($m), 2005-2010
- Table 18: Multiple Myeloma Therapeutics Market, Spain, Forecast ($m), 2010-2018
- Table 19: Multiple Myeloma Therapeutics Market, Japan, Revenue ($m), 2005-2010
- Table 20: Multiple Myeloma Therapeutics Market, Japan, Forecast ($m), 2010-2018
- Table 21: Multiple Myeloma Therapeutics - Phase III Pipeline
- Table 22: Multiple Myeloma Therapeutics - Phase II/III Pipeline
- Table 23: Multiple Myeloma Therapeutics - Phase II Pipeline
- Table 24: Multiple Myeloma Therapeutics - Phase I/II Pipeline
- Table 25: Multiple Myeloma Therapeutics - Phase I Pipeline
- Table 26: Multiple Myeloma Therapeutics - Preclinical Pipeline
- Table 27: Multiple Myeloma Therapeutics - Discovery Pipeline
- Table 28: Mechanisms of Action That Constitute the Others in the Above Pie Chart
- Table 29: Multiple Myeloma Therapeutics - Promising Drugs Under Clinical development, 2011
- Table 30: Multiple Myeloma Therapeutics - Clinical Trials by Country, 2011
- Table 31: Multiple Myeloma Therapeutics - Clinical Trials by Phase, 2011
- Table 32: Multiple Myeloma Therapeutics - Clinical Trials by Status, 2011
- Table 33: Multiple Myeloma Therapeutics - Clinical Trials by Overall Sponsors, 2011
- Table 34: Multiple Myeloma Therapeutics - Clinical Trials by Prominent Sponsors, 2011
- Table 35: Multiple Myeloma Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
- Table 36: Bristol-Myers Squibb Company, Oncology Pipeline, 2011
- Table 37: Bristol-Myers Squibb Company, Multiple Myeloma Pipeline, 2011
- Table 38: AEterna Zentaris Inc, Oncology Pipeline, 2011
- Table 39: AEterna Zentaris Inc, Multiple Myeloma Pipeline Pipeline, 2010
- Table 40: Celgene Corporation - Oncology Pipeline, 2011
- Table 41: Celgene Corporation - Multiple Myeloma Pipeline, 2011
- Table 42: Merck & Co., Inc. - Oncology Pipeline
- Table 43: Merck & Co., Inc. - Multiple Myeloma Pipeline, 2011
- Table 44: Novartis AG - Oncology Pipeline, 2011
- Table 45: Novartis AG - Multiple Myeloma Pipeline, 2011
- Table 46: Onyx Pharmaceuticals, Inc. - Oncology Pipeline, 2011
- Table 47: Onyx Pharmaceuticals, Inc. - Multiple Myeloma Pipeline, 2011
- Table 48: Johnson & Johnson - Oncology Pipeline, 2011
- Table 49: Johnson & Johnson - Multiple Myeloma Pipeline, 2011
- Table 50: PharmaMar, S. A. - Oncology Pipeline, 2011
- Table 51: PharmaMar, S. A. - Multiple Myeloma Pipeline, 2011
- Table 52: Multiple Myeloma Therapeutics, Global, Deals, 2011
List of Figures
- Figure 1: Mutliple Myeloma Therapeutics Market, Global, Revenue ($bn), 2005-2010
- Figure 2: Multiple Myeloma Therapeutics, Market Share ($m), 2010
- Figure 3: Multiple Myeloma Therapeutics Market, Global, Forecast ($bn), 2010-2018
- Figure 4: Multiple Myeloma Therapeutics, Market Share ($m), 2018
- Figure 5: Multiple Myeloma Therapeutics Market, The US, Revenue ($bn), 2005-2010
- Figure 6: Multiple Myeloma Therapeutics Market, The US, Forecast ($bn), 2010-2018
- Figure 7: Multiple Myeloma Therapeutics Market, The UK, Revenue ($m), 2005-2010
- Figure 8: Multiple Myeloma Therapeutics Market, The UK, Forecast ($m), 2010-2018
- Figure 9: Multiple Myeloma Therapeutics Market, France, Revenue ($m), 2005-2010
- Figure 10: Multiple Myeloma Therapeutics Market, France, Forecast ($m), 2010-2018
- Figure 11: Multiple Myeloma Therapeutics Market, Germany, Revenue ($m), 2005-2010
- Figure 12: Multiple Myeloma Therapeutics Market, Germany, Forecast ($m), 2010-2018
- Figure 13: Multiple Myeloma Therapeutics Market, Italy, Revenue ($m), 2005-2010
- Figure 14: Multiple Myeloma Therapeutics Market, Italy, Forecast ($m), 2010-2018
- Figure 15: Multiple Myeloma Therapeutics Market, Spain, Revenue ($m), 2005-2010
- Figure 16: Multiple MyelomaTherapeutics Market, Spain, Forecast ($m), 2010-2018
- Figure 17: Multiple Myeloma Therapeutics Market, Japan, Revenue ($m), 2005-2010
- Figure 18: Multiple Myeloma Therapeutics Market, Japan, Forecast ($m), 2010-2018
- Figure 19: Opportunity and Unmet Need for First Line Treatment of Multiple Myeloma
- Figure 20: Opportunity and Unmet Need for Treatment of Relapse/Refractory Multiple Myeloma
- Figure 21: Multiple Myeloma Therapeutics Market - Strategic Competitor Assessment of First Line Therapy, 2011
- Figure 22: MM Therapeutics - Strategic Competitor Assessment of Relapse/Refractory Multiple Myeloma Therapy, 2011
- Figure 23: Multiple Myeloma Therapeutics, Pipeline by Phase of Development, 2011
- Figure 24: Multiple Myeloma Therapeutics - Pipeline by Mechanism of Action, 2011
- Figure 25: Multiple Myeloma - Technology Trends Analytics Framework
- Figure 26: Multiple Myeloma Therapeutics - Technology Trends Analytics Framework - Description, 2011
- Figure 27: Multiple Myeloma Therapeutics - Clinical Trials by Country, 2011
- Figure 28: Multiple Myeloma Therapeutics - Clinical Trials by Phase, 2011
- Figure 29: Multiple Myeloma Therapeutics - Clinical Trials by Status, 2011
- Figure 30: Multiple Myeloma Therapeutics - Clinical Trials by Overall Sponsors, 2011
- Figure 31: Multiple Myeloma Therapeutics - Clinical Trials by Prominent Sponsors, 2011
- Figure 32: Multiple Myeloma Therapeutics - Top Companies Participating in Therapeutic Clinical Trials, 2011
- Figure 33: Multiple Myeloma Therapeutics Market, Drivers and Barriers, 2011
- Figure 34: Implications for Future Market Competition in Multiple Myeloma Therapeutic Market, 2011
- Figure 35: Multiple Myeloma Therapeutics - Pipeline by Company, 2011
- Figure 36: GlobalData Market Forecasting Model
|
